Table 1.

FDA (2017) Drug Label for Abacavir. Therapeutic Recommendations based on HLA-B*57:01 Genotype. Warnings and Precautions.

GenotypeHypersensitivity reactions
HLA-B*5701-positive patientsDue to the potential for severe, serious, and possibly fatal hypersensitivity reactions with abacavir sulfate:
All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir tablets or reinitiation of therapy with abacavir tablets, unless patients have a previously documented HLA-B*5701 allele assessment.
Abacavir tablets are contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients.

Please see 2017 Statement from the US Food and Drug Administration (FDA) for more information from the FDA. Table adapted from (1).

From: Abacavir Therapy and HLA-B*57:01 Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.